Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 629-634

  Conley, Barbara A ^a,b,c   Egorin, Merrill J ^b,c   Tait, Nancy ^b   Rosen, D Marc ^c   Sausville, Edward A ^c   Dover, George ^a,d   Fram, Robert J ^b   Van Echo, David A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; HEMOGLOBIN F; NSC 661583; TRIBUTYRIN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DYSPHORIA; FATIGUE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; UREMIA; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRODRUGS; TRIGLYCERIDES;

EID: 0031954530     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cheson, B. D., Jasperse, D. M., Chun, H. G., and Friedman, M. A. Differentiating agents in the treatment of human malignancies. Cancer Treat. Rev., 13: 129-145, 1986.
2. Samid, D., Shack, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
3. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, O., Tompkins, A. C., Weinberger, M. S., Headlee, D. J., McCall, N. A., Samid, D., and Myers, C. E. A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
4. Smith, M. A., Parkinson, D. R., Cheson, B. D., and Friedman, M. A. Retinoids in cancer therapy. J. Clin. Oncol., 10: 839-864, 1992.
5. Huang, M. E., Ye, Y. C., Chen, S. R., Chai, J. R., Lu, J. X., Zhoa, L., Gu, L. J., and Wang, Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72: 567-572, 1988.
6. Warrell, R. P., Jr., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. S., and Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med., 324: 1385-1393, 1991.
7. Prasad, K. N. Butyric acid: a small fatty acid with diverse biologic functions. Life Sci., 27: 1351-1358, 1980.
8. Tsao, D., Morita, A., Bella, A., Jr., Luu, P., and Kim, Y. S. Differential effects of sodium butyrate, dimethyl sulfoxide and retinoic acid on membrane-associated antigen, enzymes, and glycoproteins of human rectal adenocarcinoma cells. Cancer Res., 42: 1052-1058, 1982.
9. Chen, Z. X., and Breitmen, T. R. Tributyrin: a prodrug of butyric acid for potential clinical application to differentiation therapy. Cancer Res., 54: 3494-3499, 1994.
10. McCue, P. A., Gubler, M. L., Sherman, M. I., and Cohen, B. N. Sodium butyrate induces histone hyperacetylation and differentiation of murine embryonal carcinoma cells. J. Cell Biol., 98: 602-608, 1984.
11. Heerdt, B. G., Houston, M. A., and Augenlicht, L. H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res., 54: 3288-3294, 1994.
12. Novogrodsky, A., Dvir, A., Ravid, A., Shkolnik, T., Stenzel, K. H., Rubin, A. L., and Zaizov, R. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer (Phila.), 51: 9-14, 1983.
13. Miller, A. A., Kurschel, E., Osieka, R., and Schmidt, C. G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol., 23: 1283-1287, 1987.
14. Perrine, S. P., Ginger, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S. P., Vichinsky, E. P., and Olivieri, N. F. A short term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N. Engl. J. Med., 328: 81-86. 1993.
15. Yuan, Z., Eiseman, J., Plaisance, K., Sentz, D., Begora, S., Fossler, M., Young, D., and Egorin, M. Plasma pharmacokinetics (PK) of butyrate after administration of tributyrin and Na butyrate to mice and rats. Proc. Am. Assoc. Cancer Res., 35: 429, 1994.
16. Boffa, L. C., Lupton, J. R., Mariani, M. R., Ceppi, M., Newmark, H. L., Scalmati, A., and Lipkin, M. Modulation of colonic epithelial proliferation, histone acetylation, and luminal short chain fatty acids by variation in dietary fiber (wheat bran) in rats. Cancer Res., 52: 5906-5912, 1992.
17. Dover, G. J., Boyer. S. H., and Bell, W. R. Microscopic method for assaying F cell production: ultrastructure changes during infancy and in aplastic anemia. Blood, 52: 664-672, 1978.
18. Francis, G. E., Guimaraes, J. E. T. E., Berney, J. J., and Wing, M. A. Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and acute myeloid leukaemia. Leuk. Res., 9: 573-581, 1985.
19. Waxman, S., Scher, B. M., Hellinger, N., and Scher, W. Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res., 50: 3878-3887, 1990.
20. Bill, C. A., Vines, C. M., Garrett, K. C., Yamada, K., and Tofilon, P. J. Enhancement of the radiosensitivity of two human tumor cell lines by hexamethylene bisacetamide. Br. J. Cancer, 61: 563-567, 1990.
21. 3. Biochem. Pharmacol., 38: 3859-3865, 1989.
22. Fontana, J. A. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp. Cell Biol., 55: 136-144, 1987.
23. Takahashi, N., Sausville, E. A., and Breitman, T. R. N-(4-Hydroxyphenyl)retinamide (fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins. Clin. Cancer Res., 1: 637-642, 1995.
24. Lotan, R., Dawson, M. I., Zou, C. C., Jong, L., Lotan, D., and Zou, C. P. Enhanced efficacy of combinations of retinoic acid- and retinoid X receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res., 55: 232-236, 1995.